To include your compound in the COVID-19 Resource Center, submit it here.

Kuvan sapropterin dihydrochloride: Phase IIIb started

Merck's Merck Serono S.A. division began the open-label, international Phase IIIb SPARK trial to evaluate 10-20 mg/kg/day oral Kuvan

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE